Sarepta Therapeutics Announces Third Quarter 2020 Financial Results and Recent Corporate Developments
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall Street rallies as AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips below $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Wall Street rallies as AI optimism reignites and Treasury yields retreat
Sarepta Therapeutics (SRPT) Tops Q3 EPS by 29c
November 5, 2020 6:03 PM ESTSarepta Therapeutics (NASDAQ: SRPT) reported Q3 EPS of ($1.42), $0.29 better than the analyst estimate of ($1.71). Revenue for the quarter came in at $143.92 million versus the consensus estimate of $137.43 million.
Even as the pandemic created challenges throughout the third quarter, I am pleased to report that the Sarepta team was able to continue to serve... More
